Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities

Sahana Bettadapura,Katherine Dowling,Kelli Jablon,Ahmed W. Al-Humadi,Carel W. le Roux

DOI: https://doi.org/10.1038/s41366-024-01500-y

2024-03-08

International Journal of Obesity

Abstract:Glucagon-like peptide-1 (GLP-1) analogs are approved for the treatment of obesity in adults and adolescents. Reports have emerged that the weight loss effect of these medications may be related to changes in food preferences and ingestive behaviors following the treatment. Understanding the mechanisms which impact ingestive behavior could expand opportunities to develop more refined and personalized treatment options for obesity.

endocrinology & metabolism,nutrition & dietetics

What problem does this paper attempt to address?

This paper mainly discusses the changes in food preference and eating behavior after treatment with glucagon-like peptide-1 (GLP-1) analogs and how these changes affect weight management. GLP-1 analogs have been approved for the treatment of obesity in adults and adolescents. The study found that the weight loss effects of these drugs may be related to changes in food preference and eating behavior after treatment.

The authors retrieved relevant literature and analyzed the effects of GLP-1 analogs such as liraglutide, semaglutide, and exenatide on appetite, taste, eating behavior, and weight loss. The study points out that most of the research is focused on the weight loss stage, showing a reduction in short-term appetite and food intake. However, there is less research on the weight maintenance stage, and the evaluation of food intake mainly relies on subjective verbal reports, which may introduce bias.

The paper emphasizes the importance of understanding the mechanisms by which GLP-1 analogs affect eating behavior for the development of more precise and personalized treatment methods for obesity. Future research is suggested to use more objective methods to measure food intake to reduce the influence of subjective factors and consider the advantages and limitations of various measurement tools.

The study also mentions that GLP-1 receptor agonists such as semaglutide and liraglutide can reduce appetite, decrease meal size, and reduce preference for energy-dense foods in the early stages of weight loss. However, these effects may weaken during the weight maintenance stage, suggesting that once a new balance of body fat is achieved, the biological drive may weaken, leading to a regression of eating behavior to pre-intervention levels.

In summary, this paper aims to address how GLP-1 analogs alter food preference and eating behavior and how these understandings can be utilized to improve the treatment strategies for obesity.